$235.74
10.08% today
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Alnylam Pharmaceuticals, Inc Stock price

$235.74
-7.19 2.96% 1M
-32.25 12.03% 6M
+0.43 0.18% YTD
+84.26 55.62% 1Y
+73.97 45.73% 3Y
+123.60 110.22% 5Y
+132.05 127.35% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-26.42 10.08%
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Key metrics

Market capitalization $34.10b
Enterprise Value $34.15b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 15.19
P/S ratio (TTM) P/S ratio 15.17
P/B ratio (TTM) P/B ratio 505.24
Revenue growth (TTM) Revenue growth 22.97%
Revenue (TTM) Revenue $2.25b
EBIT (operating result TTM) EBIT $-176.89m
Free Cash Flow (TTM) Free Cash Flow $-42.59m
Cash position $2.69b
EPS (TTM) EPS $-2.17
P/E forward negative
P/S forward 11.75
EV/Sales forward 11.77
Short interest 2.60%
Show more

Is Alnylam Pharmaceuticals, Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Alnylam Pharmaceuticals, Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

25x Buy
74%
8x Hold
24%
1x Sell
3%

Analyst Opinions

34 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

Buy
74%
Hold
24%
Sell
3%

Financial data from Alnylam Pharmaceuticals, Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,248 2,248
23% 23%
100%
- Direct Costs 323 323
4% 4%
14%
1,925 1,925
27% 27%
86%
- Selling and Administrative Expenses 919 919
24% 24%
41%
- Research and Development Expense 1,126 1,126
12% 12%
50%
-120 -120
47% 47%
-5%
- Depreciation and Amortization 57 57
5% 5%
3%
EBIT (Operating Income) EBIT -177 -177
37% 37%
-8%
Net Profit -278 -278
37% 37%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about Alnylam Pharmaceuticals, Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alnylam Pharmaceuticals, Inc Stock News

Neutral
Business Wire
3 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www....
Neutral
Business Wire
6 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today's patients. Data were presented ...
Neutral
Business Wire
7 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits bloo...
More Alnylam Pharmaceuticals, Inc News

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Head office United States
CEO Yvonne Greenstreet
Employees 2,230
Founded 2002
Website www.alnylam.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today